Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The dystrobrevin-syntrophin complex is a critical cytoplasmic subcomplex within the larger dystrophin-associated glycoprotein complex (DGC), primarily located at the sarcolemma of muscle fibers. It consists of alpha or beta-dystrobrevin and various syntrophin isoforms (alpha, beta, or gamma), which together act as a scaffolding platform for signaling molecules such as neuronal nitric oxide synthase (nNOS) and aquaporin-4. By linking the dystrophin cytoskeleton to the extracellular matrix and intracellular signaling pathways, this complex ensures the mechanical stability of the muscle membrane during contraction and relaxation. Mutations or deficiencies in the primary DGC components, such as dystrophin, lead to the secondary loss of the dystrobrevin-syntrophin complex, resulting in progressive muscle wasting diseases like Duchenne muscular dystrophy. While few drugs target these proteins directly, they are the primary downstream beneficiaries of genetic therapies aimed at restoring dystrophin expression. Successful therapeutic intervention is often measured by the recruitment of these proteins back to the sarcolemma, which restores cellular signaling and structural integrity. Beyond muscular dystrophy, specific mutations in syntrophin have been implicated in cardiac arrhythmias like Long QT syndrome, highlighting the complex's role in regulating ion channel function.
Restoration of the dystrophin-associated glycoprotein complex (DGC) through exon skipping, stop-codon read-through, or gene replacement to stabilize the muscle cell membrane.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dystrobrevin-syntrophin complex (DB-SN complex).